肿瘤领域年度盛会——2026年美国临床肿瘤学会（ASCO 2026）年会将于2026年5月29日~6月2日在美国芝加哥举行。作为全球肿瘤学领域的顶级盛会，ASCO年会汇聚了来自世界各地的顶尖专家，共同探讨肿瘤诊疗的最新突破与临床进展。当前，ASCO官网已公布了大会摘要标题及讲者信息，【肿瘤资讯】特别整理黑色素瘤/皮肤癌领域的口头报告专场（Oral Abstract Session）、快速口头报告专场（Rapid Oral Abstract Session）和临床科学研讨会（Clinical Science Symposium）研究，与读者分享。
口头报告专场
摘要号：9500
英文标题：Individualized neoantigen therapy intismeran autogene (intismeran) plus pembrolizumab (pembro) in resected melanoma: 5-year update of the KEYNOTE-942 study.
中文标题：个体化新抗原疗法Intismeran autogene (intismeran 联合帕博利珠单抗 (pembro) 用于手术切除后的黑色素瘤治疗：KEYNOTE-942 研究的 5 年随访更新
讲者：Matteo S. Carlino, Westmead and Blacktown Hospitals, Melanoma Institute Australia, and The University of Sydney, Sydney, NSW, Australia
摘要号：9501
英文标题：A phase II study of neoadjuvant ipilimumab-nivolumab-relatlimab (INR) combination immunotherapy in high-risk resectable melanoma.
中文标题：一项关于伊匹木单抗-纳武利尤单抗-relatlimab (INR) 联合免疫疗法用于高危可切除黑色素瘤新辅助治疗的II期临床研究
讲者：Ahmad Tarhini, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
摘要号：9502
英文标题：A phase 2 study of neoadjuvant nivolumab (nivo) + relatlimab (rela) in high-risk stage II cutaneous melanoma (NeoReNi).
中文标题：一项关于纳武利尤单抗 (nivo) 联合relatlimab (rela) 新辅助治疗高危II期皮肤黑色素瘤的2期临床研究 (NeoReNi)
讲者：Georgina V. Long, Melanoma Institute Australia, The University of Sydney, Royal North Shore Hospital and Mater Hospital, Sydney, Australia
摘要号：LBA9503
英文标题：Darovasertib plus crizotinib vs investigator's choice as first-line treatment for patients with HLA-A2 negative metastatic uveal melanoma: Primary results from the OptimUM-02 trial.
中文标题：Darovasertib 联合克唑替尼对比研究者选择方案一线治疗HLA-A2阴性转移性葡萄膜黑色素瘤患者：OptimUM-02研究的主要结果
讲者：Marlana M. Orloff, Thomas Jefferson University Hospital, Philadelphia, PA
摘要号：LBA9504
英文标题：ADAM trial: A multicenter, randomized, double-blinded, placebo-controlled, phase 3 trial of adjuvant avelumab (anti-PD-L1 antibody) in patients with Merkel cell carcinoma and lymph node metastases.
中文标题：ADAM 试验：一项关于Avelumab（抗 PD-L1 抗体）辅助治疗伴有淋巴结转移的Merkel细胞癌患者的多中心、随机、双盲、安慰剂对照III期临床研究
讲者：Shailender Bhatia, University of Washington and Fred Hutchinson Cancer Center, Seattle, WA
摘要号：9506
英文标题：A phase II, multicenter, single-arm clinical trial of response-adapted definitive radiotherapy and cemiplimab-rwlc immunotherapy for locally advanced, unresectable cutaneous squamous cell carcinoma: RAMPART.
中文标题：一项关于反应适应性根治性放疗联合cemiplimab-rwlc免疫治疗局部晚期、不可切除皮肤鳞状细胞癌的多中心、单臂II期临床研究：RAMPART
讲者：Christopher A. Barker, Memorial Sloan Kettering Cancer Center, New York, NY
摘要号：LBA9505
英文标题：Updated outcomes from STAMP: Surgically treated adjuvant Merkel cell carcinoma with pembrolizumab, a phase III trial—ECOG-ACRIN EA6174.
中文标题：STAMP研究的更新结果：一项关于帕博利珠单抗辅助治疗手术切除后Merkel细胞癌的 III 期临床研究——ECOG-ACRIN EA6174
讲者：Janice M. Mehnert, New York University School of Medicine, New York, NY
摘要号：9507
英文标题：OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy with regulatable membrane-bound IL15 (mbIL15) in patients with advanced melanoma that has progressed on/after immune checkpoint inhibitors (ICI): Phase 2 results.
中文标题：OBX-115工程化肿瘤浸润淋巴细胞 (TIL) 疗法（含有可调节膜结合型 IL15）用于免疫检查点抑制剂 (ICI) 治疗进展后的晚期黑色素瘤患者：II 期临床研究结果
讲者：Allison Betof, Stanford University School of Medicine, Stanford, CA
摘要号：9508
英文标题：Patient-level clinical response dynamics in advanced melanoma with anzutresgene autoleucel (anzu-cel), a PRAME-directed T-cell receptor (TCR) T-cell therapy.
中文标题：Anzutresgene autoleucel (anzu-cel)——一种靶向 PRAME 的 T 细胞受体 (TCR) T 细胞疗法治疗晚期黑色素瘤的患者层面临床缓解动力学研究
讲者：Diwakar Davar, University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, Pittsburgh, PA
快速口头报告专场
摘要号：9512
英文标题：Phase 1b study of a brain-penetrant MEK inhibitor, PF-07799544, plus next-generation BRAF dimer inhibitor, PF-07799933, in advanced BRAF-mutant melanoma.
中文标题：一项关于脑渗透性MEK抑制剂PF-07799544联合下一代BRAF二聚体抑制剂PF-07799933治疗晚期BRAF突变型黑色素瘤的1b期临床研究
讲者：Monica F. Chen, Memorial Sloan Kettering Cancer Center, New York, NY
摘要号：9513
英文标题： Combination of vemurafenib with cobimetinib in BRAF V600E/K mutated melanoma patients to normalize LDH and optimize immunotherapy with nivolumab and ipilimumab (COWBOY): A randomized, open-label phase 2 clinical trial.
中文标题：维莫非尼联合考比替尼用于BRAF V600E/K突变型黑色素瘤患者以恢复LDH正常并优化纳武利尤单抗联合伊匹木单抗免疫治疗 (COWBOY)：一项随机、开放标签的 II 期临床试验
讲者：Kalijn Bol, MD, PhD, Radboud University Medical Center, Nijmegen, Gelderland, Netherlands
摘要号：LBA9514
英文标题：MATRiX: A randomized phase II trial of tuvusertib (ATR inhibitor) with or without avelumab in advanced anti-PD(L)-1 refractory Merkel cell carcinoma.
中文标题：MATRiX 研究：一项关于Tuvusertib（ATR 抑制剂）联合或不联合Avelumab治疗晚期抗 PD(L)-1 难治性Merkel细胞癌的随机 II 期临床研究
讲者：Evan Thomas Hall, MD, MPhil, University of Washington, Seattle, WA
摘要号：9515
英文标题：A phase II study of neoadjuvant cemiplimab in hedgehog inhibitor (HHI)-naive basal cell carcinoma of the head and neck.
中文标题：一项关于西米普利单抗新辅助治疗未接受过Hedgehog抑制剂 (HHI) 治疗的头颈部基底细胞癌的II期临床研究
讲者：Hannah L. Kenny, MD, Thomas Jefferson University Hospital, Philadelphia, PA
摘要号：9516
英文标题：Cadonilimab or ivonescimab plus axitinib in metastatic mucosal melanoma: Results from a phase Ib trial.
中文标题：卡度尼利单抗或依沃西单抗联合阿昔替尼治疗转移性黏膜黑色素瘤：一项 Ib 期临床研究的结果
讲者：待定 北京大学肿瘤医院
第一作者：毛丽丽 北京大学肿瘤医院
摘要号：LBA9517
英文标题：Neoadjuvant intralesional daromun (L19IL2/L19TNF) in resectable locally advanced melanoma: An update on the primary outcome and sensitivity analyses (EFS) from the PIVOTAL phase 3 trial.
中文标题：Daromun(L19IL2/L19TNF) 瘤内注射新辅助治疗可切除局部晚期黑色素瘤：PIVOTAL III 期临床研究主要结局和敏感性分析 (EFS) 的随访更新
讲者：Katharina C. Kaehler, MD, University Hospital (UKSH), Campus Kiel, Department of Dermatology, Kiel, Germany
摘要号：9518
英文标题：A 3-year landmark overall survival analysis of RP1 plus nivolumab in patients with anti-PD-1-failed melanoma from the IGNYTE clinical trial.
中文标题：来自IGNYTE临床试验的RP1联合纳武利尤单抗治疗抗PD-1治疗失败的黑色素瘤患者的 3 年里程碑式总生存期 (OS) 分析
讲者：Michael K.K. Wong, MD, PhD, Roswell Park Comprehensive Cancer Center, Buffalo, NY
摘要号：9519
英文标题：A phase 2 trial of IO102-IO103 and nivolumab-relatlimab in previously untreated, unresectable melanoma.
中文标题：一项关于 IO102-IO103 联合纳武利尤单抗-relatlimab治疗既往未经治疗的不可切除黑色素瘤的II期临床研究
讲者：James William Smithy, MD, MHS, Memorial Sloan Kettering Cancer Center, New York, NY
摘要号：9520
英文标题：Response-focused analyses of the impact of circadian rhythm on efficacy of first-line immunotherapy in melanoma.
中文标题：昼夜节律对黑色素瘤一线免疫治疗疗效影响的反应聚焦分析
讲者：Hemant Khandelia, MBBS, Department of Medicine/Division of Hematology and Oncology, University of Washington, and Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA
临床科学研讨会
摘要号：LBA9509
英文标题： A multicenter, randomized, controlled, open-label, phase II trial of autologous tumor-infiltrating lymphocytes (GC101 TIL) in patients with advanced melanoma.
中文标题：一项关于自体肿瘤浸润淋巴细胞（GC101 TIL）治疗晚期黑色素瘤患者的多中心、随机、对照、开放标签 II 期临床研究讲者：
讲者：斯璐 北京大学肿瘤医院
摘要号：9510
英文标题：Real-world safety of adoptive cellular therapy with lifileucel in patients with advanced melanoma.
中文标题：Lifileucel过继细胞疗法在晚期黑色素瘤患者中的真实世界安全性研究
讲者：Alexandra Haugh, MD, Massachusetts General Hospital Cancer Center, Boston, MA
摘要号： 9511
英文标题：Immunologic determinants in procured melanoma tissue as drivers of durable response to tumor-infiltrating lymphocyte therapy.
中文标题：黑色素瘤组织中的免疫决定因素作为肿瘤浸润淋巴细胞（TIL）疗法持久反应的驱动因子研究
讲者：Lilit Karapetyan, MD, MSc, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
排版编辑：肿瘤资讯-qtt
苏公网安备32059002004080号
